What is Oric Pharmaceuticals Inc (ORIC) stock price today?

Oric Pharmaceuticals Inc (ORIC) currently trades at $9.44 per share. The stock has a market capitalization of $977.21M and a P/E ratio of —x.

Is ORIC stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Oric Pharmaceuticals Inc has a Smart Value Score of 28/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is 1.31.

Is Oric Pharmaceuticals Inc financially healthy?

Oric Pharmaceuticals Inc's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of 1.31 places it in the distress.

ORIC

Oric Pharmaceuticals Inc

NASDAQ: ORIC · HEALTHCARE · BIOTECHNOLOGY

$9.44

-2.18% today

Updated 2026-04-29

Market cap

$977.21M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.47

Dividend yield

—

52W range

$5 – $15

Volume

2.1M

Market cap

$977.21M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.47

Dividend yield

—

52W range

$5 – $15

Volume

2.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

7.0

Quality

B+

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

1.3

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$21.00

+122.46%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy12 Buy1 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.01x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Altman Z 1.31 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-22.87M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-89.12M	$-100.70M	$-127.85M	$-129.47M	$-30.50M
EPS	—	—	—	—	$-1.47
Free cash flow	$-77.22M	$-86.54M	$-113.85M	$-114.08M	$-22.87M
Profit margin	—	—	—	—	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-02-24	PISCITELLI, DOMINIC	Sale	52,000	—
2026-02-24	PISCITELLI, DOMINIC	Buy	52,000	$4.36
2026-01-16	HEYMAN, RICHARD A.	Sale	3,500	$12.00

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
ORIC	$977.21M	28	4.3	3.0	5.0	7.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Oric Pharmaceuticals Inc trades at $9.44. Our Smart Value Score of 28/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 1.31, it sits in the distress.

Frequently asked questions

What is Oric Pharmaceuticals Inc's stock price?

Oric Pharmaceuticals Inc (ORIC) trades at $9.44.

Is Oric Pharmaceuticals Inc overvalued?

Smart Value Score 28/100 (Grade F, Strong Sell).

What is the price target of Oric Pharmaceuticals Inc (ORIC)?

The analyst target price is $21.00, representing +122.5% upside from the current price of $9.44.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

1.31 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.oricpharma.com

Quick metrics

P/S ratio—

ROE-41.30%

Beta1.36

50D MA$11.33

200D MA$11.02

Shares out0.10B

Float0.07B

Short ratio—

Avg volume2.1M

Performance

1 week-9.49%

1 month-25.49%

3 months-12.27%

YTD+15.40%

1 year—

3 years—

5 years—

Compare

ORIC vs LLY →ORIC vs JNJ →ORIC vs ABBV →Stock screener →